Investor Alert: Following Food and Drug Administration Panel Vote, Hagens Berman Reminds Abiomed, Inc. Investors of Jan. 15, 2013, Lead Plaintiff Deadline in Class-action Lawsuit

more+
less-

Following a Food and Drug Administration (FDA) 515 Program Intiative Advisory Panel meeting and vote on retaining the Class III designation of Abiomed, Inc.’s (NASDAQ: ABMD) (“Abiomed”) Impella 2.5 system, Hagens Berman Sobol Shapiro, LLP, a securities class-action law firm, reminds investors of the Jan. 15, 2013, deadline to seek the position of lead plaintiff in a lawsuit filed on behalf of investors.

LOADING PDF: If there are any problems, click here to download the file.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© Steve Berman, Hagens Berman | Attorney Advertising

Written by:

more+
less-

Hagens Berman on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:

Sign up to create your digest using LinkedIn*

*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.
×
Loading...
×
×